Cellivery Notifies Asia's 2nd Largest Global Pharmaceutical Company of Nucleic Acid New Drug Technology

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 3rd that it has notified the development results of cell-permeable nucleic acid therapeutics incorporating its 'pharmacological substance in vivo delivery TSDT platform technology' for the joint development of gene interference antisense oligonucleotide (ASO) therapeutic drugs with the Asia No. 2 global pharmaceutical company.

This global pharmaceutical company was seeking a cell-permeable platform technology capable of delivering oligonucleotide ASOs, which are difficult to deliver in vivo, into cells within biological tissues. They became aware of Cellivery's TSDT platform technology through the 2019 JP Morgan Bio Conference and highly evaluated the excellence of this new technology for biopharmaceutical development. According to the company, they signed a joint development contract for TSDT platform-fused oligonucleotide ASO therapeutics in February last year and commenced the project.

The global pharmaceutical company selected Cellivery's delivery technology to introduce genetic material regulators ASOs into the body to treat rare genetic diseases caused by over-expression of specific genes and abnormal post-transcriptional modifications.

The project is being conducted simultaneously in both Korea and Japan. Recently, Cellivery conjugated 25 types of its cell membrane-permeable peptides aMTD with one type of nucleic acid ASO from the global pharmaceutical company in Japan, and Cellivery evaluated the cell permeability and pharmacological efficacy of these 25 'peptide-nucleic acid conjugated pharmacological substances.'

The head of Cellivery's joint development team stated, “We conducted knockdown activity verification of disease-causing genes for the 25 conjugated pharmacological substances (aMTD-ASO). We have reported the results to the core leadership of this pharmaceutical company.”

He explained, “Oligonucleotide ASOs have faced many challenges in drug development because they are not delivered into biological tissues and cells. Cellivery’s TSDT platform technology can overcome these weaknesses. The aMTD-ASO drug substances developed in this way have been proven to possess a cell-to-cell transfer mechanism in vivo, enabling them to finally exert pharmacological efficacy.”

If the delivery technology succeeds in licensing, the global pharmaceutical company will secure a pioneering drug delivery technology that presents a new paradigm in oligonucleotide therapeutic drug development. Furthermore, the company strongly expressed its intention to recognize Cellivery as a development partner for ongoing drug development in disease areas they wish to pursue and to maintain continuous cooperation, according to the company.

This content was produced with the assistance of AI translation services.